GlassScriptPhysician profile
Maithreyi Sarma
NPI 1831631647
$674.36
in general payments reported to CMS, 2019-2025
14 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.00 · 2023: $37.13 · 2024: $176 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538 · Education: $41.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.34 |
| Education | $41.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $131.39 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $95.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $81.97 | 2024-2025 | |
| Glaxosmithkline, LLC. | $63.81 | 2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $56.84 | 2024-2025 | |
| Emd Serono, INC. | $41.63 | 2025 | |
| Janssen Pharmaceuticals, INC | $41.02 | 2025 | |
| Gilead Sciences, INC. | $29.90 | 2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $25.64 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $25.54 | 2024 | Enhertu |
| Pfizer INC. | $22.64 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $22.09 | 2023 | Somatuline Depot, Onivyde |
| Celgene Corporation | $21.85 | 2025 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $15.04 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maithreyi Sarma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.